An Unbiased Drug Screen in a Drosophila Model of LMNA-Muscular Dystrophy Identifies Calcium Channel Blockers as Potential Treatments
- 1Interdisciplinary Graduate Program in Genetics, University of Iowa, Iowa City, IA 52242, USA
- 2Department of Biochemistry and Molecular Biology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
- 3Department of Biomedical Engineering, University of Iowa, Iowa City, IA 52242, USA
Abstract
Mutations in the LMNA gene encoding A-type lamins cause multiple muscular dystrophies (LMNA-MD). Lamins are intermediate filaments with three conserved domains: an N-terminal head, a coiled-coil rod, and a C-terminal domain possessing an Ig-like fold. Missense mutations in all three domains can cause LMNA-MD by mechanisms that are not well understood. Currently, there are limited treatments for LMNA-MD beyond symptom management. In this study, our goal was to identify candidate treatments through an in vivo drug repurposing screen using Drosophila models of LMNA-MD that recapitulate aspects of the disease phenotype. Expression of LamC R264Q (Drosophila orthologue of human LMNA R249Q) in fly muscles causes muscle defects and premature death. We fed 1520, mostly FDA/EMA-approved, drugs to larvae and screened for rescue of lethality. This screen resulted in 68 positive hit drugs that partially restored viability. Molecular fingerprinting clustered a subset of these compounds into six structurally related groups, including L-type voltage-gated calcium channel inhibitors. We tested these inhibitors using multiple fly models expressing different mutant lamins and discovered that only flies expressing amino acid substitutions in the rod domain benefited, supporting a need for personalized treatments. Collectively, our findings support L-type voltage-gated calcium channel blockers as candidate treatments that warrant testing in pre-clinical models.
Related
- Integrated transcriptome and single-cell RNA sequencing identifies transient receptor potential channel-related biomarkers in ulcerative colitis
- A genome-wide CRISPR knockout screen identifies host dependency factors and potential viral-induced cell death regulators for porcine deltacoronavirus infection
- If Becker Muscular Dystrophy Initially Manifests with Heart Disease and Rhabdomyolysis, Neurological Work-up Is Imperative
- Planar covariation: a new key for the early detection of Duchenne muscular dystrophy walking behaviour
- Image-based assessment of muscle contractile performance in facioscapulohumeral muscular dystrophy: protocol of the MUSCLE+ observational study in the Netherlands
BibTeX
@article{mohar2026unbiased,
title = {{An Unbiased Drug Screen in a Drosophila Model of LMNA-Muscular Dystrophy Identifies Calcium Channel Blockers as Potential Treatments}},
author = {Nathaniel P. Mohar and Brenna A. Powers and Benjamin E. Hinz and Alex R. Bock and Hailey McCoy-Munger and Zachary Darr and Maxwell W. Shumaker and Alexander T. Wemmie and Amya Saxena and Lori L. Wallrath},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27188367},
url = {https://www.mdpi.com/1422-0067/27/18/8367},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - An Unbiased Drug Screen in a Drosophila Model of LMNA-Muscular Dystrophy Identifies Calcium Channel Blockers as Potential Treatments
AU - Nathaniel P. Mohar
AU - Brenna A. Powers
AU - Benjamin E. Hinz
AU - Alex R. Bock
AU - Hailey McCoy-Munger
AU - Zachary Darr
AU - Maxwell W. Shumaker
AU - Alexander T. Wemmie
AU - Amya Saxena
AU - Lori L. Wallrath
PY - 2026
DA - 2026/09/19
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27188367
UR - https://www.mdpi.com/1422-0067/27/18/8367
AB - Mutations in the LMNA gene encoding A-type lamins cause multiple muscular dystrophies (LMNA-MD). Lamins are intermediate filaments with three conserved domains: an N-terminal head, a coiled-coil rod, and a C-terminal domain possessing an Ig-like fold. Missense mutations in all three domains can cause LMNA-MD by mechanisms that are not well understood. Currently, there are limited treatments for LMNA-MD beyond symptom management. In this study, our goal was to identify candidate treatments through an in vivo drug repurposing screen using Drosophila models of LMNA-MD that recapitulate aspects of the disease phenotype. Expression of LamC R264Q (Drosophila orthologue of human LMNA R249Q) in fly muscles causes muscle defects and premature death. We fed 1520, mostly FDA/EMA-approved, drugs to larvae and screened for rescue of lethality. This screen resulted in 68 positive hit drugs that partially restored viability. Molecular fingerprinting clustered a subset of these compounds into six structurally related groups, including L-type voltage-gated calcium channel inhibitors. We tested these inhibitors using multiple fly models expressing different mutant lamins and discovered that only flies expressing amino acid substitutions in the rod domain benefited, supporting a need for personalized treatments. Collectively, our findings support L-type voltage-gated calcium channel blockers as candidate treatments that warrant testing in pre-clinical models.
SN - 1422-0067
ER -